Kura Oncology (NASDAQ:KURA) Insider Mollie Leoni Sells 84,929 Shares

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the sale, the insider directly owned 182,345 shares of the company’s stock, valued at $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Kura Oncology Stock Performance

Shares of KURA opened at $10.36 on Tuesday. The firm’s 50 day moving average is $9.44 and its 200-day moving average is $9.23. The stock has a market capitalization of $919.66 million, a P/E ratio of -3.09 and a beta of 0.36. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. Kura Oncology, Inc. has a 12-month low of $5.45 and a 12-month high of $12.49.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. The business had revenue of $18.27 million for the quarter, compared to the consensus estimate of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. Equities research analysts anticipate that Kura Oncology, Inc. will post -3.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp raised its stake in Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after purchasing an additional 1,587,959 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after purchasing an additional 1,121,228 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Kura Oncology by 111.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after buying an additional 965,256 shares during the period. AQR Capital Management LLC boosted its position in shares of Kura Oncology by 36.6% in the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after buying an additional 820,020 shares during the period. Finally, Qube Research & Technologies Ltd grew its holdings in shares of Kura Oncology by 63.0% during the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after buying an additional 738,761 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on KURA. Wedbush reduced their price objective on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, March 6th. Mizuho cut their target price on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 24th. Lake Street Capital initiated coverage on Kura Oncology in a research report on Tuesday, April 14th. They set a “buy” rating and a $23.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Tuesday, April 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $25.46.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.